Glycerol Phenylbutyrate – USA

Glycerol Phenylbutyrate – USA

On Jun 18, 2018, the Federal Circuit in one-liner order affirmed PTAB’s decision that method of treatment patent of drug, RAVICTI® is valid.
US 8,642,012(Hyperion; Exp: Sep. 22, 2030) claims a method of treating a patient having a urea cycle disorder comprising (a) determining a target urinary phenylacetyl glutamine (PAGN) output (b) calculating an effective initial dosage of a phenylacetic acid (PAA) prodrug selected from glyceryl tri-[4-phenylbutyrate] (HPN-100) and phenylbutyric acid (PBA) or a pharmaceutically acceptable salt of PBA, wherein the effective dosage of PAA prodrug is calculated based on a mean conversion of PAA prodrug to urinary PAGN of about 60%; and (c) administering the effective initial dosage of PAA prodrug to the patient.
Previously, on April 29, 2015, Par Pharmaceutical, Inc. filed a Petition (IPR2015-01117) requesting an inter partes review of claims 1–12 of US 8,642,012. On Nov. 4, 2015, PTAB instituted trial & Lupin joined (IPR2016-00283) that petition. On Nov. 3, 2016, PTAB found that Par has failed to carry its burden of proving by a preponderance of the evidence that claims 1–12 would have been unpatentable over the prior art.

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved